Clinical trials · New York, NY
Breast cancer clinical trials in New York
We’re tracking 244 recruiting breast cancer studies with a site in or near New York — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near New York
- NCT06395519RecruitingPhase 1/Phase 2
Study of ETX-19477 for advanced solid tumors
This trial tests an experimental drug called ETX-19477 for people with advanced solid tumors that have stopped responding to other treatments. It aims to see if the drug is safe and effective, especially for those with certain genetic changes (BRCA2 mutations).
New York, New YorkAges 18 years+ - NCT06736613RecruitingPhase 2
Blood test for tumor DNA in high-risk B-cell lymphoma
This trial uses a blood test to look for tumor DNA in people with high-risk B-cell lymphoma, to help predict if the lymphoma might spread to the brain or spinal cord. It may help doctors decide on extra treatments to prevent that spread.
New York, New YorkAges 18 years+ - NCT05837767Recruiting
Radiation study for tumors that spread to soft tissue areas
This study looks at how a planned form of palliative radiation therapy treats certain solid cancers that have spread outside the brain to larger soft-tissue areas. It may help shrink tumors and relieve symptoms, but it also asks you to meet specific safety and treatment-timing rules.
New York, New YorkAges 18 years+ - NCT06393374RecruitingPhase 3
Study of a new drug combination for residual TNBC after initial treatment
This trial tests a new combination of two drugs (sacituzumab tirumotecan and pembrolizumab) compared to standard chemotherapy for people with triple-negative breast cancer that did not fully respond to initial treatment. It aims to see if this combination helps prevent cancer from coming back.
New York, New YorkAges 18 years+ - NCT06678269RecruitingPhase 1
Abemaciclib and radiation for metastatic breast cancer
This trial tests whether a targeted therapy (abemaciclib) combined with focused radiation (SBRT) to a bone tumor can help people with advanced breast cancer. It is for patients whose cancer is hormone receptor positive and HER2 negative, and who will continue abemaciclib after radiation.
New York, New YorkAges 18 years+ - NCT05879926RecruitingPhase 3
Testing chemo after hormone therapy in premenopausal early breast cancer
This Phase 3 trial checks whether adding chemotherapy after standard hormone-blocking treatment works better for some premenopausal women with early-stage, ER-positive, HER2-negative breast cancer. It targets patients with limited lymph node spread and a lower-to-intermediate tumor “recurrence” risk score.
New York, New YorkAges 18–60 - NCT07114601RecruitingPhase 1
Study of LY4257496 for people with GRPR-positive solid tumors
This trial tests a new drug, LY4257496, in people with certain types of cancer that have a protein called GRPR on their cells. The study aims to see if the drug can help shrink tumors or slow the cancer's growth.
New York, New YorkAges 18 years+ - NCT07459673RecruitingPhase 2
HER2-positive breast cancer trial using ctDNA to guide treatment
This trial tests a personalized treatment plan for HER2-positive breast cancer that has spread. It uses a blood test to track cancer DNA and adjust therapy, including treatments that may help prevent cancer from reaching the brain. The goal is to achieve long-term remission.
New York, New YorkAges 18 years+ - NCT05696626RecruitingPhase 3
Test a new pill plus abemaciclib versus standard therapy
This Phase 3 study compares lasofoxifene plus abemaciclib versus fulvestrant plus abemaciclib for ER-positive, HER2-negative breast cancer that has an ESR1 mutation. It looks for better tumor control in people whose cancer has progressed on hormone therapy (an aromatase inhibitor) and who meet specific safety and testing requirements.
New York, New YorkAges 18 years+ - NCT05219695Recruiting
Imaging and controlled heat treatment for breast tumors
This study uses special ultrasound-like imaging to guide a controlled heat treatment during planned surgery for certain breast tumors. It may help doctors better see and treat tumor tissue while you already have surgery scheduled.
New York, New YorkAges 18 years+ - NCT05216432RecruitingPhase 1
RLY-2608 for PIK3CA-mutant advanced solid tumors and breast cancer
This early study (Phase 1) tests RLY-2608, a targeted cancer drug for tumors with a PIK3CA mutation. It studies the drug alone and combined with hormone therapy (and sometimes CDK4/6 or CDK4 medicines) to see safety, dose, and whether it can shrink tumors.
New York, New YorkAges 18 years+ - NCT07335354Recruiting
Decision tool for breast reconstruction after mastectomy
This study is testing a decision tool to help people who are thinking about breast reconstruction surgery after a mastectomy. The tool is designed to help you and your doctor make a more informed choice.
New York, New YorkAges 18 years+ - NCT05134779Recruiting
Study aims to tailor cancer treatment to your biology
This study looks at how genes, the cancer environment, and your immune system interact to develop treatments that work better for people with breast cancer. It may help researchers learn why some treatments work for certain people and not others.
New York, New YorkAges 18–90 - NCT04389632RecruitingPhase 1
Sigvotatug vedotin for advanced solid tumors that spread
This early-stage study tests a drug called sigvotatug vedotin in people with advanced solid cancers that cannot be removed or have spread. It aims to see how well the treatment works and what side effects it causes.
New York, New YorkAges 18 years+ - NCT05059444Recruiting
Blood test study to watch for cancer coming back
This study looks at whether blood tests can detect signs that cancer may return after curative-intent treatment. You would have blood drawn around your usual follow-up visits for up to 5 years, and your de-identified health data would be shared with study investigators.
New York, New YorkAges 18 years+ - NCT05570253RecruitingPhase 2
SDX-7320 plus eribulin for metastatic triple-negative breast cancer
This Phase 2 study tests whether adding SDX-7320 to eribulin can work better for people with triple-negative metastatic breast cancer. It focuses on patients who have had prior chemotherapy and who also show signs of metabolic imbalance such as higher body weight or higher HbA1c.
New York, New YorkAges 18 years+ - NCT07225309Recruiting
Meaning-Centered Therapy for Mexican Adults with Advanced Cancer
This study tests a therapy program called Meaning-Centered Therapy designed to help adults in Mexico with advanced cancer find meaning and improve their well-being. It involves sessions delivered by trained providers at the National Cancer Institute in Mexico (INCan).
New York, New YorkAges 18 years+ - NCT06275126Recruiting
Choosing the Best Surgery for Young Women with Breast Cancer
This study looks at how to make the best surgical choices for young women with breast cancer. It compares different surgery options to help guide treatment decisions.
New York, New YorkAges 18–44 - NCT06695845RecruitingPhase 2
Study of zanidatamab for HER2-positive solid tumors
This trial tests a drug called zanidatamab in people with advanced solid tumors that have high levels of HER2 protein (called HER2-positive). It aims to see if zanidatamab can shrink or slow the growth of these tumors.
New York, New YorkAges 18 years+ - NCT06757634RecruitingPhase 3
A study of gedatolisib for first-line advanced breast cancer
This trial tests a new targeted therapy called gedatolisib for people with HR-positive, HER2-negative advanced breast cancer who have not yet received treatment for metastatic disease. It aims to see if adding this drug to standard hormone therapy can help control the cancer longer.
New York, New YorkAges 18 years+ - NCT06458712RecruitingPhase 1
Testing a new drug for advanced cancers with gene changes
This study tests a new oral drug, DSB2455, for people with advanced breast, prostate, ovarian, or pancreatic cancers that have certain gene changes. It aims to see if the drug is safe and whether it helps shrink or control the cancer.
New York, New YorkAges 18 years+ - NCT05633654RecruitingPhase 3
Test drug combo versus standard care for triple-negative breast cancer
This trial tests a cancer antibody-drug combination plus pembrolizumab (immunotherapy) versus standard treatment. It’s for people with triple-negative breast cancer that still has invasive disease in the breast or lymph nodes after surgery and chemotherapy before surgery.
New York, New YorkAges 18 years+ - NCT07612215RecruitingPhase 1/Phase 2
Elacestrant for Advanced Triple-Positive Breast Cancer
This trial tests a new drug called elacestrant for advanced breast cancer that is triple-positive (positive for three hormone receptors: ER, PR, and HER2). The drug may help slow or shrink cancer that has progressed despite previous treatments.
New York, New YorkAges 18 years+ - NCT05496829Recruiting
Improving how people take breast-cancer and heart medicines
This trial tests an intervention to help improve how equitably people take their prescribed breast cancer hormone therapy and heart-related prevention medicines. It may help if you have had trouble taking these medications as directed.
New York, New YorkAges 18–99
Hear when a new Breast cancer trial opens near New York, NY
We’ll email you when one opens near New York, NY — at most once a week, no account needed, unsubscribe anytime.
Breast cancer trials in other cities
Where these studies are running near New York
Institutions with a site for the recruiting breast cancer studies listed above.
- Memorial Sloan Kettering Cancer Center · 13 studies
- Memorial Sloan Kettering Basking Ridge · 6 studies
- Memorial Sloan Kettering Bergen · 6 studies
- Memorial Sloan Kettering Commack · 6 studies
- Memorial Sloan Kettering Monmouth · 6 studies
- Memorial Sloan Kettering Nassau · 6 studies
- Columbia University Irving Medical Center · 4 studies
- Memorial Sloan Kettering Cancer Center - Westchester · 4 studies
What taking part in a breast cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting breast cancer studies in New York.
Common questions
- Are there breast cancer clinical trials near New York?
- Yes. We're currently tracking 244 recruiting breast cancer studies with a site near New York, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a breast cancer study near New York?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in New York to take part?
- Not necessarily. These studies have a site near New York, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a breast cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New breast cancer studies open near New York regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.